Ipratropium bromide + Albuterol sulfate Rx
Generic Name and Formulations:
Ipratropium bromide 0.5 mg/3 mL (0.017%), albuterol (as sulfate) 2.5 mg/3 mL (0.083%); soln for inh.
Various generic manufacturers
Indications for Ipratropium bromide + Albuterol sulfate:
COPD when a second aerosol bronchodilator is needed.
≥18yrs: 1 vial by nebulizer 4–6 times daily.
<18yrs: not recommended.
Not for primary treatment of acute attack. Avoid excessive use. Discontinue if paradoxical bronchospasm or cardiovascular effects occur. Cardiovascular disease (eg, coronary insufficiency, arrhythmias, hypertension). Hyperthyroidism. Diabetes. Seizure disorders. Narrow angle glaucoma. GI or GU obstruction. Hepatic or renal disease. Avoid eyes. Pregnancy (Cat.C). Labor & delivery. Nursing mothers: not recommended.
Anticholinergic + beta-2 agonist.
Avoid MAOIs, tricyclics within 14 days (increased cardiovascular effects). Caution with other anticholinergics, sympathomimetics, drugs that lower potassium. Monitor digoxin. Antagonized by β-blockers.
Lung disorders, pharyngitis, chest pain, GI disturbances, bronchitis, UTI, leg cramps, pain, voice changes, anticholinergic effects, nervousness, headache, dizziness, insomnia, tachycardia, hypokalemia, paradoxical bronchospasm.
Formerly known under the brand name DuoNeb.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC